Is pediatric IBD treatment different than in adults?

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 2, 2012, Pages 137-150

  Lev Tzion, R ^a   Turner, D ^b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Colitis, ulcerative; Crohn disease; Enteral nutrition; Growth

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; HUMAN GROWTH HORMONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; SEX HORMONE; TUMOR NECROSIS FACTOR INHIBITOR;

AGE DISTRIBUTION; CANCER RISK; CHILD GROWTH; CLINICAL FEATURE; CROHN DISEASE; DELAYED PUBERTY; DIET THERAPY; DISEASE COURSE; DOSE RESPONSE; ENTERIC FEEDING; ENTERITIS; GROWTH DISORDER; HEALTH CARE; HUMAN; INTESTINE SURGERY; OSTEOPENIA; PATHOGENESIS; PATIENT COMPLIANCE; PEDIATRICS; PSYCHOLOGICAL ASPECT; PUBERTY; REMISSION; REVIEW;

ADULT; AGE FACTORS; CHILD; HUMANS; INFLAMMATORY BOWEL DISEASES; NUTRITION THERAPY;

EID: 84864761722     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
2. Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis 2008; 14 Suppl 2:S9-11.
3. Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at a younger age? J Pediatr Gastroenterol Nutr 2011;53:141-4.
4. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39.
5. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40.
6. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998;42:309-11.
7. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5-36.
8. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
9. Polito JM, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6.
10. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18:509-23.
11. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.
12. Gold BD, Westra SJ, Graeme-Cook FM. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-2003. A 14-month-old boy with recurrent abdominal distention and diarrhea. N Engl J Med 2003;349:2541-9.
13. Levine A, Kugathasan S, Annese V, Biank V, Leshinsky-Silver E, Davidovich O et al. Pediatric onset Crohn's colitis is characterized by genotype-dependent age-related susceptibility. Inflamm Bowel Dis 2007;13:1509-15.
14. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22.
15. Levine A. Pediatric inflammatory bowel disease: is it different? Dig Dis 2009;27:212-4.
16. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:839-49.
17. Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? Dig Dis 2009;27:404-11.
18. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:513-23.
19. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:83-100.
20. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205-10.
21. Deboer MD, Li Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res 2011;69:34-9.
22. Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004;38:270-5.
23. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001;142:4818-26.
24. Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987;62:123-7.
25. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:75-81.
26. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
27. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;102:2804-12; quiz 3, 13.
28. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6.
29. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-30.
30. Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632-6.
31. Denson LA, Kim MO, Bezold R, Carey R, Osuntokun B, Nylund C et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010;51:130-9.
32. Wong SC, Kumar P, Galloway PJ, Blair JC, Didi M, Dalzell AM et al. A preliminary trial of the effect of recombinant human growth hormone on shortterm linear growth and glucose homeostasis in children with Crohn's disease. Clinical endocrinology 2011;74:599-607.
33. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997;76:325-9.
34. Bradney M, Karlsson MK, Duan Y, Stuckey S, Bass S, Seeman E. Heterogeneity in the growth of the axial and appendicular skeleton in boys: implications for the pathogenesis of bone fragility in men. J Bone Miner Res 2000;15:1871-8.
35. Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;53:11-25.
36. Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998;115:36-41.
37. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005;100:2031-5.
38. Whitten KE, Leach ST, Bohane TD, Woodhead HJ, Day AS. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol 2010;45:399-405.
39. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008;6:1378-84.
40. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22.
41. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010;105:1430-6.
42. Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EIet al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011;106:574-88.
43. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS et al. Induction and Maintenance Therapy with Infliximab for Children with Moderate-to-Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2011.
44. Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:659-66.
45. Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009;104:2566-71.
46. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9.
47. Hyams J, Griffiths A, Markowitz J, Baldassano B, Faubion W, Colletti R. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children (DDW 2011, abstract 450). In: Gastroenterology 2011 [Epub ahead of print].
48. Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007;44:185-91.
49. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010;16:953-61.
50. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
51. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007:CD000542.
52. Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007;26:795-806.
53. Markowitz J. Early inflammatory bowel disease: different treatment response to specific or all medications? Dig Dis 2009;27:358-65.
54. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
55. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
56. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
57. Vernier-Massouille G, Balde M, Salleron J, Turek D, Dupas JL, Mouterde O et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13.
58. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
59. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
60. Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, Dé Angelis GL et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
61. de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14:353-8.
62. Hyams J, Crandall W, Kugathasan S. Disease duration does not affect outcome following infliximab inchildren with Crohn's disease. Am J Gastroenterol 2008;103:S533-S4.
63. Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006;130:1069-77.
64. Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, Crandall W et al. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010;8:789-94.
65. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947-53.
66. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.
67. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011;106:699-712.
68. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;l40:1817-26.e2.
69. Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011;17:2488-96.
70. Kasirer Y, Turner D. Management issues in adolescents with Crohn's disease - current practice. World Journal of Gastroenterology.
71. Hyams JS. Risk/benefit strategies must be employed in the management of pediatric Crohn's disease. Dig Dis 2009;27:291-6.
72. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
73. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
74. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
75. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
76. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.e1.
77. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
78. Fuchs Y, Markowitz J, Weinstein T, Kohn N, Choi-Rosen J, Levine J. Pediatric inflammatory bowel disease and imaging-related radiation: are we increasing the likelihood of malignancy? J Pediatr Gastroenterol Nutr 2011;52:280-5.
79. Dayan B, Turner D. Pediatric radiation doses and IBD. Inflamm Bowel Dis 2011.
80. Landi B, Ann TN, Cortot A, Soule JC, Rene E, Gendre JP et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-53.
81. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections fections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
82. Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? Arch Surg 1973;107:329-33.
83. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
84. Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005;50:1471-5.
85. Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther 2009:30:501-7.
86. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
87. Sandhu BK, Fell JM, Beattie RM, Wilson DC, Jenkins H; on Behalf of the IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition. Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010 [Epub ahead of print].
88. Pacilli M, Eaton S, Fell JM, Rawat D, Clarke S, Haddad MJ. Surgery in children with Crohn disease refractory to medical therapy. J Pediatr Gastroenterol Nutr 2011;52:286-90.
89. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
90. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006;55:1575-80.
91. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg 2011 [Epub ahead of print].
92. Mackner LM, Crandall WV, Szigethy EM. Psychosocial functioning in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2006;12:239-44.
93. Deshmukh P, Kulkarni G, Lackamp J. Inflammatory bowel disease in children: psychological and psychiatric issues. Curr Psychiatry Rep 2010;12:222-8.
94. Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011:CD006913.
95. Hommel KA, Denson LA, Crandall WV, Mackner LM. Behavioral Functioning and Treatment Adherence in Pediatric Inflammatory Bowel Disease: Review and Recommendations for Practice. Gastroenterol Hepatol (N Y) 2008;4:785.
96. Smith BA, Shuchman M. Problem of nonadherence in chronically ill adolescents: strategies for assessment and intervention. Curr Opin Pediatr 2005;17:613-8.
97. Greenley RN, Stephens M, Doughty A, Raboin T, Kugathasan S. Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:36-41.
98. Baldassano R, Ferry G, Griffiths A, Mack D, Markowitz J, Winter H. Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002;34:245-8.
99. Leung Y, Heyman MB, Mahadevan U. Transitioning the adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis 2011;17:2169-73.